Hatem Soliman, MD
Immunotherapy has had a challenging journey breaking through the breast cancer treatment landscape. Recently, responses have been seen in some patients with triple-negative breast cancer (TNBC), signaling a potential role for immunotherapy in this tumor type.
TNBC is a heterogeneous group of breast cancer that is made up of several subtypes. It is traditionally defined as breast cancer with <1% staining of estrogen receptor and progesterone receptor, and it is negative for amplification or overexpression of HER2.
... to read the full story